



# The University of Bradford Institutional Repository

<http://bradscholars.brad.ac.uk>

This work is made available online in accordance with publisher policies. Please refer to the repository record for this item and our Policy Document available from the repository home page for further information.

To see the final version of this work please visit the publisher's website. Access to the published online version may require a subscription.

**Link to publisher's version:** <http://dx.doi.org/10.1038/srep33026>

**Citation:** Elkashef SM, Allison SJ, Sadiq M et al. (2016) Polysialic acid sustains cancer cell survival and migratory capacity in a hypoxic environment. *Scientific Reports*. 6: Article number 33026.

**Copyright statement:** © The Author(s) 2016. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>



# SCIENTIFIC REPORTS



OPEN

## Polysialic acid sustains cancer cell survival and migratory capacity in a hypoxic environment

Sara M. Elkashef<sup>1</sup>, Simon J. Allison<sup>2</sup>, Maria Sadiq<sup>1</sup>, Haneen A. Basheer<sup>1</sup>,  
Goreti Ribeiro Morais<sup>1</sup>, Paul M. Loadman<sup>1</sup>, Klaus Pors<sup>1</sup> & Robert A. Falconer<sup>1</sup>

Received: 28 May 2016  
Accepted: 15 August 2016  
Published: 09 September 2016

Polysialic acid (polySia) is a unique carbohydrate polymer expressed on the surface of NCAM (neuronal cell adhesion molecule) in a number of cancers where it modulates cell-cell and cell-matrix adhesion, migration, invasion and metastasis and is strongly associated with poor clinical prognosis. We have carried out the first investigation into the effect of polySia expression on the behaviour of cancer cells in hypoxia, a key source of chemoresistance in tumours. The role of polysialylation and associated tumour cell migration and cell adhesion were studied in hypoxia, along with effects on cell survival and the potential role of HIF-1. Our findings provide the first evidence that polySia expression sustains migratory capacity and is associated with tumour cell survival in hypoxia. Initial mechanistic studies indicate a potential role for HIF-1 in sustaining polySia-mediated migratory capacity, but not cell survival. These data add to the growing body of evidence pointing to a crucial role for the polysialyltransferases (polySTs) in neuroendocrine tumour progression and provide the first evidence to suggest that polySia is associated with an aggressive phenotype in tumour hypoxia. These results have significant potential implications for polyST inhibition as an anti-metastatic therapeutic strategy and for targeting hypoxic cancer cells.

Polysialic acid (polySia) is an  $\alpha$ -2,8-glycosidically linked polymer of sialic acid, and a developmentally regulated post-translational modification of NCAM (neuronal cell adhesion molecule)<sup>1</sup>. Cancers of neuroendocrine-origin exhibit selective high level expression of polySia-NCAM as part of the tumour glycocalyx, a term used to describe the myriad of functionally-important carbohydrates that are to be found on the surface of cancer cells<sup>2</sup>. Tumours where polySia expression has been identified notably include neuroblastoma<sup>3,4</sup>, lung cancer<sup>5,6</sup> and many others<sup>1,7–11</sup>. Crucially, whilst high levels are expressed during embryonic development, peripheral adult organs do not express polySia-NCAM. This means that the polysialyltransferase (polyST) enzymes (ST8SiaII and ST8SiaIV) responsible for polySia biosynthesis<sup>12</sup> have received considerable interest as novel anti-metastatic drug targets, particularly ST8SiaII, which is thought to be the prominent enzyme in tumours<sup>1</sup>.

PolySia-NCAM expression strongly correlates with the migration and invasion of tumour cells<sup>13</sup> and with aggressive, metastatic disease and poor clinical prognosis in the clinic<sup>1</sup>. Its detailed roles in tumour growth and dissemination continue to emerge, but involve disruption of homo- and heterophilic NCAM interactions, and in modulation of key intracellular signalling pathways, notably FGFR-1, ERK1/2, FAK and c-MET/ALK<sup>1,14,15</sup>. Furthermore, it has long been proposed that polySia-NCAM expression may protect the tumour cell from immunosurveillance mechanisms, in a manner analogous to bacteria expressing polySia<sup>16</sup> and that it is closely associated with tumour chemoresistance<sup>17</sup>.

The tumour microenvironment is intimately connected with the evolution of cancers and the limited success of cancer treatments. Hypoxia, a condition of low oxygen tension occurring in poorly vascularised areas of tumours, has profound effects on cancer cell growth<sup>18,19</sup>, metastasis<sup>20,21</sup>, susceptibility to apoptosis<sup>22,23</sup> and resistance to radiotherapy and chemotherapy<sup>24,25</sup>. Within solid tumours, oxygen delivery to neoplastic and stromal cells in different regions of the tumour varies considerably due to the chaotic nature of the tumour vasculature and the diffusion limit of oxygen of just a few hundred micrometres. Oxygen gradients exist across the tumour with decreasing levels of oxygen as distance from a blood vessel increases. Whilst different levels of hypoxia are thus likely to exist in different parts of the tumour, in general, hypoxic cancer cells are associated with a more

<sup>1</sup>Institute of Cancer Therapeutics, Faculty of Life Sciences, University of Bradford, West Yorkshire BD7 1DP, U.K.

<sup>2</sup>Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield HD1 3DH, U.K. Correspondence and requests for materials should be addressed to R.A.F. (email: r.a.falconer1@bradford.ac.uk)

aggressive, invasive phenotype<sup>26–28</sup>. The altered glycosylation of cancer cells appears to play a key role in this; promoting loss of cell-cell adhesion and cell migration<sup>29,30</sup>. However, how glycosylation changes under hypoxia and what effect, if any, this has on the behaviour of cancer cells, such as their growth, survival and invasive potential remain largely unexplored. Given the key role played by polySia in neuroendocrine tumour progression, we hypothesised that polySia may play a crucial role in tumour cell behaviour under hypoxic conditions.

## Materials and Methods

**Cell lines.** Human neuroblastoma SH-SY5Y (ATCC<sup>®</sup> CRL2266<sup>™</sup>) and DLD-1 colorectal adenocarcinoma (ATCC<sup>®</sup> CCL221<sup>™</sup>) cell lines were obtained from the American Type Culture Collection (ATCC). Human neuroblastoma SH-SY5Y cells were maintained in MEM medium and nutrient mixture F-12 Ham (1:1), supplemented with 10% foetal bovine serum, 1% sodium pyruvate and 1% glutamine. DLD-1 colorectal adenocarcinoma cell lines were maintained in RPMI media supplemented with 10% foetal bovine serum, 1% sodium pyruvate and 1% glutamine. C6-STX and C6-WT cells were obtained from the Fukuda group, Sanford-Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA (for full details, see Suzuki *et al.*)<sup>31</sup>. Briefly, C6-STX glioma cells were prepared by transfecting wild-type C6 cells (C6-WT) with the pcDNA3-STX plasmid inserted with cDNA encoded full length human ST8SiaII (also known as STX)<sup>31</sup>. Both cell lines were maintained in minimum essential medium (MEM Alpha Eagle) with ultraglutamine I, deoxyribonucleoside and ribonucleosides supplemented with 10% foetal bovine serum. All cell lines were maintained in a humid atmosphere of 5% CO<sub>2</sub> and 95% air at 37°C.

For studies carried out under conditions of low oxygen tension (“hypoxic conditions”), all media used was incubated for at least 48 hours under hypoxic conditions (0.1% oxygen) before being added to the cells.

**MTT cell viability assay.** C6 glioma cells ( $5 \times 10^3$  cells/well) were seeded in 96-well plates. After overnight attachment, the cells were treated with different concentrations of cobalt chloride (Sigma–Aldrich) to induce pseudohypoxia. Following 24 h treatment, cells were washed and fresh media was added. Cells were incubated for another 72 hours and MTT (0.5 mg/ml) was then added followed by incubation for a further 4 hours. The MTT metabolic product (formazan) was dissolved in DMSO (200 µL), and its absorbance was measured at 560 nm. Cell survival was calculated in relation to control (vehicle-treated) cells.

**In vitro cell migration assay.** Effects on tumour cell migration were analysed using a simple 2D scratch assay<sup>13,32</sup>. Cells were seeded into six-well plates at different concentrations ( $1 \times 10^6$  cells for SH-SY5Y,  $0.5 \times 10^6$  cells for C6 and  $0.8 \times 10^6$  cells for DLD-1), and plates were then incubated overnight at 37°C in a 5% CO<sub>2</sub> humidified atmosphere. Once a confluent monolayer had formed, a 200 µl pipette tip was used to create a scratch wound. The monolayer was then washed with growth medium (1 ml) to remove floating cells and replaced with fresh medium (2 ml) containing only 2% FBS to limit cell proliferation. For experiments under hypoxia, the scratch was performed in a hypoxia station (Whitley H35 hypoxystation; Don Whitley, UK) at 0.1% O<sub>2</sub> and hypoxia-equilibrated media was used. Images of the scratch at the start of the experiment were acquired using a Lumascope 500 microscope (Etaluma, USA) and reference points were marked to obtain the same field during the image acquisition after the incubation.

The plates were incubated in either normoxic (i.e. normal laboratory conditions) or hypoxic conditions for 16, 24 and 41 hours for C6, SH-SY5Y and DLD-1 cells respectively. After incubation, plates were placed under the Lumascope 500 microscope, reference points were matched, the photographed region acquired at the first image was aligned and a second image was acquired.

The images acquired were analysed quantitatively by using Image J software. For each image, distances between one side of scratch and the other were measured at certain intervals (µm). By comparing the images from time 0 to the last time point the % wound closure was calculated.

**Chromatographic cell-based analysis of polySia expression.** C6 cells were seeded at the density of  $2 \times 10^5$  cells/well in a six-well plate and incubated at 37°C in either hypoxic or normoxic conditions. After 48 hours, cells were collected by trypsinisation followed by centrifugation for 5 minutes at 1000 rpm. Using routine mild acidic hydrolysis for polySia solubilisation<sup>33,34</sup>, cell pellets were treated with 100 µL of 0.5% Igepal CA-630 (in distilled water) followed by incubation at 37°C for 0.5–1 h and vortex mixing for 5 minutes. The insoluble material was removed by centrifugation and the supernatant was used for analysis. For Endo-N treatment for polySia solubilisation, cells were treated with Endo-N (3 µg/ml) for 24 hours prior collecting the media. One well was used as negative control where no Endo-N was added.

For determination of polySia content, samples were hydrolysed in 0.1 M trifluoroacetic acid (TFA) for 2 h at 80°C. TFA was removed under vacuum and the resulting sialic acid residues were incubated with the DMB reagent for 24 h at 4°C as described previously<sup>13</sup>.

**Mass spectrometric analysis of DMB-sialic acid.** DMB-sialic acid was subjected to analysis by electrospray UPLC-MS using an Acquity UPLC Waters system and a Quattro Premier XE (Waters corporation, USA) mass spectrometer and an Acquity UPLC BEH C18 column (2.1 × 100 mm). The mobile phases used were: ammonium formate (5 mM; mobile phase A) and methanol (mobile phase B), with a flow rate of 0.3 ml/min and isocratic method of 20% mobile phase B. The peaks and masses were integrated using Masslynx software. The source temperature was set to 120°C. MRM transitions acquired at unit resolution in both the Q1 and Q3 quadrupoles to maximise specificity. Cone voltage (CV) was adjusted to 25 V while collision energy (CE) was adjusted to 20 V using positive ionisation mode. The transitions detected are summarised in Table 1.

Transition	Molecular weight (MW)	Charge Z	Parent ion (m/z)	Daughter ion (m/z)	CV (V)	CE (eV)	Dwell time (sec)
1	425.4	+1	426	229.23	25	20	0.2
2	425.4	+1	426	313.02	25	20	0.2

**Table 1.** Transition data for mass spectrometric analysis of DMB-sialic acid.

**Cell-cell adhesion assay.** C6 cells were incubated under hypoxic or normoxic conditions for 48 hours at 37 °C. Matrigel® (200 µl, 40 µg/ml) (VWR, USA) solution was added to each well of a 24-well plate and incubated at 37 °C. After two hours, excess Matrigel was removed and the wells were washed twice with cold PBS. Blocking solution (DMEM media with %10 FBS, 500 µl) was added to each well. The plates were then incubated at 37 °C. After 30 minutes the wells were washed once with cold PBS and fresh culture medium (200 µl) was added and the plates were incubated at 37 °C.

$2 \times 10^4$  cells in 100 µl medium were added to the pre-coated 24-well plate. Culture medium (300 µl) was added to one well to be used as a blank to calculate the background staining. The plates were incubated at 37 °C for 30 minutes. Non-adherent cells were removed by inverting the plates on a plastic reservoir. Wells were washed two times with 300 µl ice-cold PBS containing 1 mM CaCl<sub>2</sub> and 1 mM MgCl<sub>2</sub>. Cells were fixed by adding ice-cold 100% methanol (300 µl). After 10 minutes, wells were washed with PBS three times and of 0.5% crystal violet solution, prepared in 20% ethanol (100 µl), was added. Plates were placed on a shaker and incubated with crystal violet solution for 10 minutes at room temperature. Excess crystal violet solution was then removed. Crystal violet was then recovered by adding 200 µl of 100% methanol to each well. 100 µl of the extracted crystal violet was transferred to 96-well plate. Absorbance of the samples was measured spectrophotometrically at a wavelength of 540 nm. The background absorbance of multi-well plates was also measured and subtracted from the 540 nm measurements.

Absorbance readings acquired for each sample were analysed quantitatively. Background absorbance of the multi-well plates was subtracted and the % cell adhesion relative to C6-WT cells was calculated (% adhesion = mean absorbance of the C6-WT cells / mean absorbance of C6-STX cells in the same condition  $\times$  100). Three independent experiments were carried out, each comprising 4 technical replicates.

**Trypan blue exclusion assay for cell viability.** C6 cells were seeded in T75 flasks with seeding density of  $2.5 \times 10^4$  cells/flask, with one flask per treatment incubated in normoxic conditions and the other in hypoxic (0.1% O<sub>2</sub>) conditions for 96 hours. 0.4% solution of trypan blue was prepared in PBS solution (pH 7.2) and 0.1 mL of trypan blue stock solution was added to 1 mL of trypsinised cells. Each haemocytometer chamber was loaded with 10 µl of the solution and examined immediately under a microscope at low magnification. The number of trypan blue-stained cells and the number of total cells was counted. The % trypan blue-stained cells was calculated as follows: % dead cells = (Average number of trypan blue-stained cells count  $\div$  average total cell count)  $\times$  100. % cell viability was also calculated as follows: % Viable cells = [1.00 - (Number of blue cells  $\div$  Number of total cells)]  $\times$  100.

**Flow cytometry (Annexin V apoptosis detection assay).** C6 cells were seeded ( $8 \times 10^5$  cells) in T75 flasks under normoxic or hypoxic (0.1% O<sub>2</sub>) conditions at 37 °C. After incubation for 96 h, media was collected and cells were trypsinised. Trypsinised cells, along with the collected media, were then centrifuged at 1000 g for 5 minutes. After centrifugation, media was discarded and cell pellets were re-suspended in HEPES buffer (1 ml) as provided with the Annexin V\_FLUOS staining kit (Roche) in accordance with the manufacturer's instructions. Cells were further centrifuged (1500 g, 5 minutes) and pellets were re-suspended in 100 µl HEPES buffer containing Propidium iodide and Annexin V as previously described<sup>35</sup>. After 15 minutes, 0.5 ml of Annexin-binding buffer was added and cell samples were analysed by flow cytometry.

**Western blot analysis.** For CoCl<sub>2</sub> treatment, C6-STX and C6-WT cells were seeded at a density of  $2 \times 10^5$  cells/well in a six-well plate and incubated for 24 hours at 37 °C in a 5% CO<sub>2</sub> humidified atmosphere to allow cells to adhere. After 24 hours, medium was removed and fresh medium containing different concentrations of CoCl<sub>2</sub> was added. Two wells were used as a control where no CoCl<sub>2</sub> was added. After 16 hours cells were collected.

Samples were resolved on 12% polyacrylamide gels and blotted onto PVDF membranes (Amersham). Non-specific antibody binding was blocked via incubation with skimmed milk (0.05 g/ml) and the blot was probed with rat anti-HIF-1 $\alpha$  antibody (R&D systems, UK) (1:100 dilution) or rat anti-LDH-A antibody (Abcam, UK) (1:500 dilution) overnight at 4 °C. Antibody reactivity was detected by horseradish peroxidase (HRP)-conjugated antibody and chemiluminescence using ECL-Plus (Amersham).

**RT-PCR analysis.** *RNA purification and quantification.* C6 were incubated in normoxic or hypoxic conditions for 48 h, after which RNA was extracted using the RNeasy Mini Kit (Qiagen, UK) according to the manufacturer's instructions. The concentration and quality of the eluted RNA were determined by measuring absorbance at 260 nm and 280 nm using a Nanodrop™2000 (Thermo Fisher Scientific) spectrophotometer and determining the 260/280 ratio.

2000 ng of total RNA was reverse transcribed into single-stranded cDNA using the High Capacity cDNA Reverse Transcription Kit (Life technologies) according to manufacturer's handbook. Once the reaction finished, samples were stored at  $-20$  °C.

Target gene (C6 cell lines)	TaqMan gene expression assay
GLUT1	Rn01402419_g1
HK2	Rn00562457_m1
LDH-A	Rn00820751_g1

**Table 2. Validated Taqman primers utilised in PCR experiments.**

**Real-time quantitative PCR.** qPCR was carried out using the TaqMan Universal PCR Master Mix (Applied Biosystems). The PCR reaction consisted of 12.5 µl of 2X master mix, 1.25 µl of 20X TaqMan Gene Expression Assay Mix, and 11.25 µl cDNA diluted in dH<sub>2</sub>O. The cDNA samples were diluted 1:5 and 2 µl of diluted cDNA was used per reaction. A 96-well MicroAmp Optical plate (Applied Biosystems) was used and all reactions were performed in triplicate. The validated Taqman primers (Applied Biosystems) utilised are listed in Table 2. qPCR reactions were performed using a AB7500 Real time PCR system (Applied Biosystems). The fold-change in gene expression was determined using the 2- $\Delta\Delta$ CT method<sup>36</sup>.

**Statistics.** A minimum of three independent biological experiments were performed for all studies. Statistical analyses were performed using Excel software. Differences between two groups were evaluated with Student's t test (Two tailed).

## Results and Discussion

**Evaluation of polySia expression in C6-STX cells under hypoxic conditions.** Cells were initially evaluated to assess the effect of hypoxia on polySia expression. The isogenic C6 glioma cells served as an ideal model in this regard. First reported by the Fukuda group<sup>31</sup>, C6-STX cells have been engineered to express ST8SiaII and thus express polysialylated NCAM (polySia-NCAM)<sup>13</sup>. The merits of these cells as a model for polySia-expressing cancer cells are well established<sup>13,31,37</sup>. C6-STX cells migrate and invade significantly faster than C6-WT (wild type) cells *in vitro*<sup>13,31</sup> and *in vivo*<sup>31</sup>. Our own experiments have additionally confirmed that levels of polySia expression in C6-STX cells are similar to those observed in naturally expressing cell lines (e.g. SH-SY5Y, data not shown). C6-STX and C6-WT cells are otherwise genetically identical (expressing NCAM, the acceptor for polySia), only differing in the expression of ST8SiaII and associated polySia<sup>31</sup>. We were thus able to reasonably attribute any effects observed in the subsequent experiments to the presence of polySia.

C6-STX cells were incubated at 37 °C in either 0.1% oxygen, 5% carbon dioxide and 95% nitrogen (hypoxia) or 5% carbon dioxide and 95% air (normoxia). After 48 h, cells were harvested and polySia expression was quantified using a cell-based chromatographic assay (see Methods).

Interestingly, a comparison of the polySia expression of C6-STX cells under hypoxia and normoxia revealed a marked difference. C6-STX cells exhibited a significant reduction in polySia expression of polySia under hypoxia conditions ( $61.8 \pm 4.8\%$  of that measured under normoxia,  $P = 0.01$ , Fig. 1). The use of C6-WT cells as a negative control confirmed a lack of polySia expression under both conditions (data not shown) and validated the assay given the isogenic nature of the cells. Cell-based quantification of cell-surface polySia was carried out using both endoneuraminidase-N (Endo-N, an enzyme that selectively cleaves polySia) and mild acidic hydrolysis for the removal of polySia from the cell surface, two techniques routinely available to us in our laboratory. Similar results were obtained from both experiments, giving confidence in the result obtained ( $SD \pm 10\%$ ).


These data show that steady-state levels of exogenously expressed polySia are reduced in C6-STX cells under hypoxic conditions. These findings are exciting and represent the first such evidence that hypoxia affects polySia expression in tumour cells. That said, these results are consistent with previous studies that have more broadly suggested that acute hypoxia produces a degree of glycolyx degradation<sup>38</sup>.

**Effect of hypoxia on polySia-mediated tumour cell migration.** PolySia has been shown to play a key role in tumour cell migration. Generally speaking, there are many reports demonstrating that hypoxia modulates cancer cell migration<sup>39,40</sup>. Given our determination that polySia levels were reduced under hypoxic conditions, implications for tumour cell migration were investigated.

The effect of polySia expression on tumour cell migration under hypoxic conditions was once again analysed using the C6 glioma cell line pair: C6-STX (polySia<sup>+</sup>/NCAM<sup>+</sup>) and C6-WT (polySia<sup>-</sup>/NCAM<sup>+</sup>). We, along with our collaborators before us, have previously demonstrated that C6-STX cells migrate significantly faster than C6-WT cells in normoxia<sup>13,31</sup>. We additionally evaluated naturally polySia-expressing neuroblastoma cell line SH-SY5Y (polySia<sup>+</sup>/NCAM<sup>+</sup>), and utilised DLD-1 colorectal cancer cells as a negative control (polySia<sup>-</sup>/NCAM<sup>-</sup>). Migration was evaluated using a simple scratch assay<sup>32</sup>, routinely used in our laboratory. For the two polySia-expressing cell lines (C6-STX and SH-SY5Y), no difference in cell migration was observed between the hypoxic and normoxic conditions. This is intriguing given our finding that polySia expression is reduced in C6-STX cells under hypoxia. Interestingly, the control cells (C6-WT and DLD-1), which do not express polySia, showed a significant and marked reduction in cell migration under hypoxia (Fig. 2a,b).

Given these results, we hypothesised that a polySia inhibitor would reduce polySia expression further and thus may reduce migration of polySia-expressing cells under hypoxia. We have previously demonstrated that polySia inhibitor ICT-3176 reduces tumour cell migration in polySia-expressing cells (including C6-STX and SH-SY5Y cells) with high selectivity<sup>41</sup>. C6-STX cells were thus treated with ICT-3176 (250 µM) under hypoxic conditions. Cell migration was compared with non-treated cells. Treatment of the cells with ICT-3176 resulted in significant inhibition of C6-STX cell migration ( $22.4 \pm 2.5\%$ , Fig. 2c,d) in hypoxia. As expected, ICT-3176 treatment showed no effect on C6-WT cells.





**Figure 1. Effect of hypoxia (48 hours, 0.1% O<sub>2</sub>) on polySia expression in C6-STX cells.** (a) Mild acidic hydrolysis combined with UPLC/MS/MS analysis used to detect polySia in C6-STX cells under normoxia (upper trace) and hypoxia (lower trace, after 48 hours). Y-axis represents % abundance of polySia, x-axis represents time. (b) Elution standard for standard DMB-labelled sialic acid (upper trace) and negative control sample where no Endo-N was added as described in the material and methods section (lower trace). (c) Quantification of the mean polySia levels as determined by HPLC. (\*\*P ≤ 0.01).

Taken together, these results demonstrate that the polySia-expressing tumour cells evaluated under hypoxia are able to maintain the migratory capacity observed in normoxia, and this is despite the significant reduction in polySia expression levels noted earlier. Furthermore, polyST inhibition results in reduced migration in hypoxia, as it does in normoxia.


**Effect of hypoxia on polySia-mediated cancer cell-matrix adhesion.** It was previously reported that polySia modulates cancer cell adhesion through modulation of NCAM-NCAM interactions and NCAM interaction with other molecules in addition to exerting a repulsive force created by the negative charge on the polySia chains. Furthermore, evidence has been reported suggesting that polySia and hypoxia modulate the c-MET signalling pathway, which has a significant role on cancer cell adhesion<sup>42</sup>.

In order to investigate the effect of hypoxia on polySia-mediated tumour cell-matrix adhesion, an assay was performed with C6-STX and C6-WT cells after 48 hour growth in either normoxic or hypoxic conditions. C6-STX cells were less able to adhere to Matrigel<sup>®</sup> than C6-WT cells, irrespective of oxygen conditions. Adhesion capacity in polySia-expressing C6-STX cells was approximately 15% less than that observed in control C6-WT cells. There was no difference, however, in cell adhesiveness between normoxic and hypoxic conditions for either C6-STX or C6-WT cells (P = 0.9 for C6-STX cell adhesion in hypoxia compared to normoxia; P = 0.3 for C6-WT adhesion in hypoxia compared to normoxia, see Supplementary data S1).

These results suggest that unlike migration, hypoxia does not appear to have any significant effect on polySia-mediated cell-matrix adhesion, at least to Matrigel in this case. The lack of a difference between adhesion observed in hypoxia and normoxia is perhaps surprising given the lower quantity of polySia expressed by C6-STX cells under hypoxic conditions. It may be that polySia modulates cell adhesion by interacting with different signalling pathways under hypoxic conditions, such as c-MET which is over expressed in hypoxic conditions<sup>43,44</sup>. This is interesting and certainly worthy of further exploration.

**Effect of polySia expression on cancer cell survival in hypoxia.** We next considered whether polySia plays any role in cell survival under hypoxic conditions. In order to determine this, C6-STX and C6-WT cells were subjected to hypoxia for 96 h while control cells were incubated for the same duration under normoxic conditions. After 96 h, cells were examined under the microscope and were subsequently collected. Viable and dead cell counts were determined using trypan blue staining. Interestingly, polySia-expressing cells were associated with significantly higher cancer cell viability under hypoxic conditions compared to controls (Fig. 3a). The trypan blue exclusion assay revealed that after 96 h under hypoxia, C6-WT control cells demonstrated significantly reduced viability, as evidenced by a greater number of trypan blue-stained cells (Fig. 3b). C6-WT cells demonstrated cell viability of 80% (i.e. 19.7 ± 3.8% trypan blue-stained cells, Fig. 3b) compared to C6-STX polySia-expressing cells with cell viability of 98% (i.e. 1.6 ± 0.6% trypan-blue stained cells, Fig. 3b).


In order to further analyse this reduction in cell survival observed under hypoxia and potential mechanisms of increased cell death in the C6-WT cells, levels of apoptosis in hypoxia-cultured C6-STX and C6-WT cells were determined. As shown in Fig. 3c, the apoptotic fraction of C6-WT cells was significantly higher than that of C6-STX cells under hypoxic conditions (18.5% apoptotic cells in C6-WT compared to 4.9% apoptotic cells in C6-STX, i.e. 73.5% less apoptosis in C6-STX cells, Fig. 3d, Table 3), while no significant difference was observed in normoxia. These results strongly suggest that polySia expression plays a key role in enhancing C6 glioma cell survival in hypoxia.



**Figure 2. Effect of polySia on the migration of tumour cells under hypoxic conditions.** (a) Representative images of the migration of SH-SY5Y, C6-STX cells (expressing polySia), and control cell lines C6-WT and DLD-1 using time-lapse microscopy under hypoxia, showing the wound size immediately and 16, 24 and 41 hours after scratching; (b) Graph representing the quantification of wound closure calculated by measuring the reduction of wound area over time, using Image J software. Wound closure under hypoxia is calculated as a percentage of wound closure under normoxia for each cell line; (c) Effect of ICT-3176 treatment on C6-STX cell migration under hypoxia; (d) Representative images of the migration of C6-STX cells after treatment with ICT-3176 compared to control untreated cells under hypoxia.  $T_1 = 16$ h (C6-STX, C6-WT); 24h (SH-SY5Y); 41h (DLD-1). (\*\* $P \leq 0.01$ ).

For comparison, we additionally performed this experiment using SH-SY5Y cells, which naturally express polySia. The levels of apoptosis in SH-SY5Y cells cultured in hypoxia and normoxia were similarly compared. No significant difference in the percentage of viable cells cultured in hypoxia or normoxia was identified, mirroring the results obtained using C6-STX cells (Supplementary data S2).

**Investigating a potential role of hypoxia-inducible factor-1 (HIF-1) in the altered behaviour of polySia-expressing tumour cells under hypoxic conditions.** A critical mediator of the hypoxic response is the transcription factor hypoxia-inducible factor 1 (HIF-1) that upregulates expression of proteins that promote angiogenesis, anaerobic metabolism, metastasis and many other survival pathways<sup>45</sup>. Glucose metabolism is upregulated by many cancer cells under hypoxia, generating lactate through the enzyme lactate dehydrogenase A (LDH-A)<sup>46</sup>, an established HIF-1a target gene<sup>47,48</sup>. HIF-1 activity in tumours depends on the



**Figure 3. Effect of polySia expression on the survival of cancer cells in hypoxia.** (a) Morphological change in C6-STX and C6-WT cells after incubation under hypoxic or normoxic conditions for 96 h; (b) Trypan blue exclusion assay, showing the effect of hypoxia on the viability of C6 cells. The graph represents the mean of three independent experiments; (c) Flow cytometry analysis of C6-STX and C6-WT cells apoptosis under hypoxic and normoxic conditions after 96 h. The x-axis shows levels of annexin V cellular staining whereas levels of propidium iodide staining are shown on the y-axis; lower left quadrant of dot plots 1–4: live cells (annexin V-negative, propidium iodide-negative); lower right quadrant: early apoptotic cells (annexin V-positive, propidium iodide-negative); upper right quadrant: late apoptotic or necrotic cells (annexin V-positive, propidium iodide-positive); upper left quadrant: mechanically damaged cells (annexin V-negative, propidium iodide-positive). C1 represents C6-WT in normoxia, C2 represents C6-WT cells in hypoxia, C3 represents C6-STX cells in normoxia, C4 represents C6-STX cells in hypoxia; (d) Percentage of annexin V staining of cell lines under each condition. (\*\* $P \leq 0.01$ ; \*\*\* $P \leq 0.001$ ).


Cell line and conditions	Apoptotic cells (%)		Viable cells (%)
	Late apoptotic (necrotic)	Early apoptotic	
C6-WT (Normoxia)	0.64 ± 0.19	1.75 ± 1.24	96.22 ± 1.14
C6-WT (Hypoxia)	10.6 ± 0.60	7.89 ± 1.24	79.03 ± 1.50
C6-STX (Normoxia)	0.53 ± 0.13	1.33 ± 0.19	97.48 ± 0.37
C6-STX (Hypoxia)	2.16 ± 0.29	2.75 ± 0.46	94.45 ± 0.04

**Table 3. Summary percentages of annexin V-stained C6 cells under normoxia and hypoxia.**

availability of the HIF-1 $\alpha$  subunit, the levels of which increase under hypoxic conditions and through the activation of oncogenes and/or inactivation of tumour suppressor genes<sup>49,50</sup>.

In order to investigate whether HIF-1 $\alpha$  plays any role in the altered polySia-mediated cancer cell behaviour observed under hypoxic conditions, we utilised an established experimental tool to investigate HIF-1 dependency of hypoxia-induced phenomena, namely cobalt chloride (CoCl<sub>2</sub>). CoCl<sub>2</sub> administration under normoxia is thus a simple means by which to mimic the HIF-1-dependent processes that normally occur under hypoxia. CoCl<sub>2</sub> stabilises HIF-1 $\alpha$  by blocking post-translational modification by prolyl hydroxylase<sup>51,52</sup>. Whereas CoCl<sub>2</sub>





**Figure 4. Effect of CoCl<sub>2</sub> treatment on C6 cell lines.** (a) Determination of IC<sub>50</sub> of CoCl<sub>2</sub> in C6-STX and C6-WT cell lines; (b) Quantification of migration of C6-STX and C6-WT cells after treatment with CoCl<sub>2</sub>, calculated by measuring the reduction of wound area over time using Image J software. The percentage of C6-WT wound closure after CoCl<sub>2</sub> treatment is calculated as a percentage of the C6-STX wound closure. (\*P < 0.05).

lacks exquisite selectivity for HIF-1 $\alpha$ , it is routinely used in this context as a tool prior to more complex experiments<sup>53,54</sup>. In the next few experiments, the effect of HIF-1 $\alpha$  induction using CoCl<sub>2</sub> on the key polySia-induced behavioural changes of cancer cells under hypoxia were examined.

**Determination of CoCl<sub>2</sub> cytotoxicity.** In order to determine the most suitable CoCl<sub>2</sub> concentrations for studying the effect of HIF1 $\alpha$  induction on both migration and survival of C6 cell lines, an MTT viability assay was performed.


In this experiment, the viability of C6-STX and C6-WT cells was examined after incubation with different concentrations of CoCl<sub>2</sub> for 24 hours to determine IC<sub>50</sub> values. These were determined to be  $258 \pm 10 \mu\text{M}$  for C6-STX cells and  $289 \pm 12 \mu\text{M}$  for C6-WT cells (Fig. 4a). For the migration assay, a concentration of CoCl<sub>2</sub> that did not cause a significant reduction in the viability of either cell line was used, i.e.  $100 \mu\text{M}$ . For studying the ability of cells to survive under stress conditions,  $200 \mu\text{M}$  of CoCl<sub>2</sub> was utilised, a concentration causing approximately 20% loss in viability of cell population.

In the absence of being able to reliably detect changes in HIF-1 $\alpha$  expression directly, we focused instead on induction of LDH-A expression to confirm effects of CoCl<sub>2</sub>, which are well established. Whilst important in itself, LDH-A induction by CoCl<sub>2</sub> has additionally been routinely utilised by others as an indirect indicative marker of transcriptionally active and functional HIF-1 $\alpha$  expression, given its strong correlation with HIF-1 $\alpha$  expression<sup>55,56</sup>. Expression of LDH-A in both C6-STX and C6-WT CoCl<sub>2</sub>-treated cells was significantly higher than control untreated cells. On this basis, we could additionally assume induction of HIF-1 $\alpha$  expression and pseudohypoxia (Supplementary data S4).

**Effect of CoCl<sub>2</sub> on polySia-mediated tumour cell migration.** In order to investigate whether the effect of polySia expression on enhancing migration of cancer cells under hypoxic conditions is HIF-1 $\alpha$ -related, the migration of C6-STX and C6-WT cells was examined following treatment with  $100 \mu\text{M}$  CoCl<sub>2</sub> (a non-toxic concentration, as determined above). Both C6-STX and C6-WT cells exhibited a significant reduction in tumour cell migration following CoCl<sub>2</sub> treatment (Supplementary data S3). However, CoCl<sub>2</sub> had a greater effect on C6-WT cells than C6-STX cells ( $35 \pm 15\%$  greater migration in C6-STX cells compared with C6-WT cells,  $P = 0.02$ , Fig. 4b). When considered in conjunction with the results obtained under hypoxia (Fig. 2a), this suggests a link between polySia-mediated migration of tumour cells under hypoxic conditions and LDH-A induction, with implications for HIF-1 $\alpha$ .

**Effect of CoCl<sub>2</sub> on polySia-expressing cancer cell survival.** Following our observation the polySia-expressing tumour cells exhibit enhanced cell survival under hypoxia, we evaluated the effect of CoCl<sub>2</sub> on cell survival. Percentage cell survival of C6-STX and C6-WT cells was examined after incubation with CoCl<sub>2</sub> ( $200 \mu\text{M}$ ; a concentration selected to study the ability of cells to survive under stress conditions) using the trypan blue exclusion assay. In contrast to the results obtained under hypoxia, no significant difference in cell survival was observed between C6-STX and C6-WT cells ( $P = 0.26$ , Supplementary data S5). This suggests that the enhancement of cell survival induced by polySia expression under hypoxic conditions may not be correlated to HIF-1 $\alpha$  upregulation.

**Differential expression of selected HIF-1 $\alpha$  induced genes in C6-STX versus C6-WT cells under hypoxia.** Possible cross-talk between polySia and glucose transporters has been previously suggested: *N*-Acetyl-D-mannosamine (ManNAc) and *N*-acetyl-D-glucosamine (GlcNAc) are the essential precursors of *N*-acetylneuraminic acid (NeuAc), the precursor monomer of polySia. Studies on the specificity of the ManNAc



**Figure 5.** Fold-change in gene expression of selected hypoxia target genes under hypoxic conditions in C6-STX compared to C6-WT cells. (\* $P \leq 0.05$ ).

transport system have revealed that addition to the uptake mixture of glucose, fructose, mannose, glucosamine, mannosamine and GlcNAc (5 mM), but not other sugars, caused a marked inhibition in ManNAc transport (70, 60, 70, 60, 65 and 85%, respectively)<sup>57,58</sup>. Although this effect was observed in *E. coli*, given the link between hypoxia and increased glucose metabolism in cancer cells, this raised the question of possible cross-talk between polySia and these processes. In initial studies, we selected three key glucose metabolism regulators, namely glucose transporter 1 (GLUT-1), hexokinase 2 (HK-2) and the aforementioned LDH-A<sup>55</sup> for evaluation<sup>59–61</sup>. The change in expression of these genes was measured under hypoxia and normalised to expression under normoxia.

Gene analysis of the C6 isogenic cells revealed a significant increase in LDH-A gene expression in C6-STX cells under hypoxic conditions as compared to WT cells. This is a significant finding, suggesting a possible role for LDH-A in polySia-mediated changes in cancer cell behaviour in hypoxia (Fig. 5). LDH-A has previously been reported to promote cancer cell survival in multiple cancer cell lines<sup>35,46,62</sup>, and has also been shown to promote cancer cell migration under hypoxic conditions<sup>63</sup>.

## Conclusion

The role of polySia in neuroendocrine tumours in tumour cell growth, dissemination and metastasis has now been widely reported. Whilst polySia expression has previously been proposed to be associated with chemoresistance, the significance of polySia expression in a hypoxic environment has not been studied. We have shown that while hypoxia leads to a reduction in polySia expression, this is strongly associated with increased cell survival, and sustains a migratory capacity. Initial mechanistic studies indicate a potential role for HIF-1 in sustaining polySia-mediated migratory capacity, but not cell survival. Furthermore, our study additionally provides the first evidence of a role for LDH-A, a key regulator of glucose metabolism under hypoxia in cancer cells, in these processes.

This study paves the way for more detailed studies in a broader array of neuroendocrine cancer cell lines, and invites further investigations using more complex *in vitro* models (e.g. 3D spheroids) and ultimately *in vivo*. Our ability to modulate polySia expression using small molecule polyST inhibitor ICT-3176, in conjunction with our striking finding that cells engineered to express polySia exhibit significantly enhanced survival in a hypoxic environment, raises exciting therapeutic implications for the targeting of hypoxic cells and for future anti-metastatic and combination therapies.

## References

- Falconer, R. A., Errington, R. J., Shnyder, S. D., Smith, P. J. & Patterson, L. H. Polysialyltransferase: a new target in metastatic cancer. *Curr. Cancer Drug Targets* **12**, 925–939 (2012).
- Pinho, S. S. & Reis, C. A. Glycosylation in cancer: mechanisms and clinical implications. *Nature Rev. Cancer* **15**, 540–555, (2015).
- Hildebrandt, H. *et al.* Polysialic acid on the neural cell adhesion molecule correlates with expression of polysialyltransferases and promotes neuroblastoma cell growth. *Cancer Res.* **58**, 779–784 (1998).
- Valentiner, U., Muhlenhoff, M., Lehmann, U., Hildebrandt, H. & Schumacher, U. Expression of the neural cell adhesion molecule and polysialic acid in human neuroblastoma cell lines. *Int. J. Oncol.* **39**, 417–424 (2011).
- Tanaka, F. *et al.* Prognostic significance of polysialic acid expression in resected non-small cell lung cancer. *Cancer Res.* **61**, 1666–1670 (2001).
- Tanaka, F. *et al.* Expression of Polysialic Acid and STX, a Human Polysialyltransferase, Is Correlated with Tumor Progression in Non-Small Cell Lung Cancer. *Cancer Res.* **60**, 3072–3080 (2000).
- Roth, J. *et al.* Presence of the long chain form of polysialic acid of the neural cell adhesion molecule in Wilms' tumor. Identification of a cell adhesion molecule as an oncodevelopmental antigen and implications for tumor histogenesis. *Am. J. Pathol.* **133**, 227–240 (1988).
- Figarella-Branger, D., Durbec, P. & Rougon, G. Differential spectrum of expression of neural cell adhesion molecule isoforms and L1 adhesion molecules on human neuroectodermal tumors. *Cancer Res.* **50**, 6364–6370 (1990).
- Lahr, G. *et al.* Neural cell adhesion molecules in rat endocrine tissues and tumor cells: distribution and molecular analysis. *Endocrinology* **132**, 1207–1217 (1993).

10. Komminoth, P. *et al.* Polysialic Acid of the Neural Cell Adhesion Molecule in the Human Thyroid: A Marker for Medullary Thyroid Carcinoma and Primary C-Cell Hyperplasia: An Immunohistochemical Study on 79 Thyroid Lesions. *Am. J. Surg. Pathol.* **18**, 399–411 (1994).
11. Trouillas, J. *et al.* Polysialylated neural cell adhesion molecules expressed in human pituitary tumors and related to extrasellar invasion. *J. Neurosurg.* **98**, 1084–1093 (2003).
12. Wang, X. *et al.* Enhanced expression of polysialic acid correlates with malignant phenotype in breast cancer cell lines and clinical tissue samples. *Int. J. Mol. Medicine* **37**, 197–206 (2016).
13. Al-Saraireh, Y. M. *et al.* Pharmacological inhibition of polysialyltransferase ST8SiaII modulates tumour cell migration. *PLoS One* **8**, e73366 (2013).
14. Li, J., Dai, G., Cheng, Y. B., Qi, X. & Geng, M. Y. Polysialylation promotes neural cell adhesion molecule-mediated cell migration in a fibroblast growth factor receptor-dependent manner, but independent of adhesion capability. *Glycobiology* **21**, 1010–1018 (2011).
15. Seidenfaden, R., Krauter, A., Schertzinger, F., Gerardy-Schahn, R. & Hildebrandt, H. Polysialic acid directs tumor cell growth by controlling heterophilic neural cell adhesion molecule interactions. *Mol. Cell. Biol.* **23**, 5908–5918 (2003).
16. Freiburger, F. *et al.* Biochemical characterization of a *Neisseria meningitidis* polysialyltransferase reveals novel functional motifs in bacterial sialyltransferases. *Mol. Microbiol.* **65**, 1258–1275 (2007).
17. Blaheta, R. A. *et al.* Chemoresistance induces enhanced adhesion and transendothelial penetration of neuroblastoma cells by down-regulating NCAM surface expression. *BMC Cancer* **6**, 294 (2006).
18. Harris, A. L. Hypoxia—a key regulatory factor in tumour growth. *Nat. Rev. Cancer* **2**, 38–47 (2002).
19. Kunz, M. & Ibrahim, S. M. Molecular responses to hypoxia in tumor cells. *Mol. Cancer* **2**, 23 (2003).
20. Subarsky, P. & Hill, R. P. The hypoxic tumour microenvironment and metastatic progression. *Clin. Exp. Metastasis* **20**, 237–250 (2003).
21. Gilkes, D. M., Semenza, G. L. & Wirtz, D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. *Nat. Rev. Cancer* **14**, 430–439 (2014).
22. Greijer, A. E. & van der Wall, E. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. *J. Clin. Pathol.* **57**, 1009–1014 (2004).
23. Sermeus, A. *et al.* Hypoxia-induced modulation of apoptosis and BCL-2 family proteins in different cancer cell types. *PLoS One* **7**, e47519 (2012).
24. Fardin, P. *et al.* A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients. *Mol. Cancer* **9**, 185 (2010).
25. Brown, J. M. Tumor hypoxia in cancer therapy. *Methods Enzymol.* **435**, 297–321 (2007).
26. Padhani, A. R., Krohn, K. A., Lewis, J. S. & Alber, M. Imaging oxygenation of human tumours. *Eur. Radiol.* **17**, 861–872 (2007).
27. Vaupel, P., Kallinowski, F. & Okunieff, P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. *Cancer Res.* **49**, 6449–6465 (1989).
28. Hockel, M. & Vaupel, P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. *J. Natl. Cancer Inst.* **93**, 266–276 (2001).
29. Fujimoto, I., Bruses, J. L. & Rutishauser, U. Regulation of cell adhesion by polysialic acid. Effects on cadherin, immunoglobulin cell adhesion molecule, and integrin function and independence from neural cell adhesion molecule binding or signaling activity. *J. Biol. Chem.* **276**, 31745–31751 (2001).
30. Guan, F., Wang, X. & He, F. Promotion of cell migration by neural cell adhesion molecule (NCAM) is enhanced by PSA in a polysialyltransferase-specific manner. *PLoS One* **10**, e0124237 (2015).
31. Suzuki, M. *et al.* Polysialic acid facilitates tumor invasion by glioma cells. *Glycobiology* **15**, 887–894 (2005).
32. Liang, C. C., Park, A. Y. & Guan, J. L. *In vitro* scratch assay: a convenient and inexpensive method for analysis of cell migration *in vitro*. *Nat. Protoc.* **2**, 329–333 (2007).
33. Inoue, S. & Inoue, Y. Ultrasensitive analysis of sialic acids and oligo/polysialic acids by fluorometric high-performance liquid chromatography. *Methods Enzymol.* **362**, 543–560 (2003).
34. Nishimura, S. *et al.* Comparison of Analytical Methods to Detect Polysialic Acid. *J. Glycomics Lipidomics* **4**, 113 (2014).
35. Allison, S. J. *et al.* Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathways. *Oncogenesis* **3**, e102 (2014).
36. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2<sup>-ΔΔC<sub>T</sub></sup> Method. *Methods* **25**, 402–408 (2001).
37. Grant, C. A. *et al.* The Effect of Polysialic Acid Expression on Glioma Cell Nano-mechanics. *Bionanoscience* **6**, 81–84 (2016).
38. Johansson, P. I. *et al.* Effect of acute hypobaric hypoxia on the endothelial glycocalyx and digital reactive hyperemia in humans. *Front. Physiol.* **5**, 459 (2014).
39. Joseph, J. V. *et al.* Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1α-ZEB1 axis. *Cancer Lett.* **359**, 107–116 (2015).
40. Nagelkerke, A. *et al.* Hypoxia stimulates migration of breast cancer cells via the PERK/ATF4/LAMP3-arm of the unfolded protein response. *Breast Cancer Res.* **15**, R2 (2013).
41. Elkashef, S. M. *et al.* Polysialyltransferase ST8SiaII: A novel target for the treatment of neuroblastoma. *Cancer Res.* **75** (Suppl 15), 5431 (2015).
42. Tate, A. *et al.* Met-Independent Hepatocyte Growth Factor-mediated regulation of cell adhesion in human prostate cancer cells. *BMC Cancer* **6**, 197 (2006).
43. Organ, S. L. & Tsao, M. S. An overview of the c-MET signaling pathway. *Ther. Adv. Med. Oncol.* **3**, S7–S19 (2011).
44. Sierra, J. R. & Tsao, M. S. c-MET as a potential therapeutic target and biomarker in cancer. *Ther. Adv. Med. Oncol.* **3**, S21–S35 (2011).
45. Koh, M. Y., Spivak-Kroizman, T. R. & Powis, G. HIF-1α and cancer therapy. *Recent Results Cancer Res.* **180**, 15–34 (2010).
46. Le, A. *et al.* Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. *Proc. Natl. Acad. Sci. USA* **107**, 2037–2042 (2010).
47. Semenza, G. L. *et al.* Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. *J. Biol. Chem.* **271**, 32529–32537 (1996).
48. Semenza, G. L. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. *J. Clin. Invest.* **123**, 3664–3671 (2013).
49. Ziello, J. E., Jovin, I. S. & Huang, Y. Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. *Yale J. Biol. Med.* **80**, 51–60 (2007).
50. Powis, G. & Kirkpatrick, L. Hypoxia inducible factor-1α as a cancer drug target. *Mol. Cancer Ther.* **3**, 647–654 (2004).
51. An, W. G. *et al.* Stabilization of wild-type p53 by hypoxia-inducible factor 1α. *Nature* **392**, 405–408 (1998).
52. Yeom, C. J. *et al.* Visualization of hypoxia-inducible factor-1 transcriptional activation in C6 glioma using luciferase and sodium iodide symporter genes. *J. Nucl. Med.* **49**, 1489–1497 (2008).
53. Ardyanto, T. D., Osaki, M., Tokuyasu, N., Nagahama, Y. & Ito, H. CoCl<sub>2</sub>-induced HIF-1α expression correlates with proliferation and apoptosis in MKN-1 cells: a possible role for the PI3K/Akt pathway. *Int. J. Oncol.* **29**, 549–555 (2006).
54. Piret, J. P., Mottet, D., Raes, M. & Michiels, C. CoCl<sub>2</sub>, a chemical inducer of hypoxia-inducible factor-1, and hypoxia reduce apoptotic cell death in hepatoma cell line HepG2. *Ann. N. Y. Acad. Sci.* **973**, 443–447 (2002).
55. Denko, N. C. Hypoxia, HIF1 and glucose metabolism in the solid tumour. *Nature Rev. Cancer* **8**, 705–713 (2008).

56. Hu, C. J., Wang, L. Y., Chodosh, L. A., Keith, B. & Simon, M. C. Differential Roles of Hypoxia-Inducible Factor 1 $\alpha$  (HIF-1 $\alpha$ ) and HIF-2 $\alpha$  in Hypoxic Gene Regulation. *Mol. Cell. Biol.* **23**, 9361–9374 (2003).
57. Revilla-Nuin, B., Reglero, A., Ferrero, M. A. & Rodriguez-Aparicio, L. B. Uptake of N-acetyl-D-mannosamine: an essential intermediate in polysialic acid biosynthesis by *Escherichia coli* K92. *FEBS Lett.* **449**, 183–186 (1999).
58. Revilla-Nuin, B. *et al.* Transport of N-acetyl-D-mannosamine and N-acetyl-D-glucosamine in *Escherichia coli* K1: effect on capsular polysialic acid production. *FEBS Lett.* **511**, 97–101 (2002).
59. Jiang, S. *et al.* A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells. *EMBO J.* **31**, 1985–1998 (2012).
60. Airley, R. *et al.* Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. *Clin Cancer Res* **7**, 928–934 (2001).
61. Han, T. *et al.* How does cancer cell metabolism affect tumor migration and invasion? *Cell Adh. Migr.* **7**, 395–403 (2013).
62. Fantin, V. R., St-Pierre, J. & Leder, P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. *Cancer Cell* **9**, 425–434 (2006).
63. Maftouh, M. *et al.* Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia. *Br. J. Cancer* **110**, 172–182 (2014).

## Acknowledgements

Prof Minoru Fukuda (Sanford Burnham Prebys Medical Discovery Institute, USA) is thanked for providing the C6 cells utilised in this study. Members of the ICT team are thanked for technical assistance. Dr. Lina Elsalem is thanked for useful discussions. This work was primarily supported by a PhD studentship for SME (RAF) and partly by Yorkshire Cancer Research (PML, KP, RAF), a Prostate Cancer UK studentship for MS (KP) and a Wellcome Trust grant (RAF).

## Author Contributions

S.M.E. designed the experiments in conjunction with R.A.F., performed all experiments except those carried out by the individuals listed, analysed data, prepared the figures and co-wrote/edited the manuscript. S.J.A. assisted with flow cytometry experiments, provided input into experimental design and edited the manuscript. M.S. performed the RT-PCR experiments. H.A.B. performed the western blots. G.R.M. synthesised ICT-3176. P.M.L. co-supervised the work and edited the manuscript. K.P. provided input into experimental design, co-supervised elements of the work and edited the manuscript. R.A.F. oversaw the project, contributed to data analysis/discussion and co-wrote and edited the manuscript.

## Additional Information

**Supplementary information** accompanies this paper at <http://www.nature.com/srep>

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Elkashef, S. M. *et al.* Polysialic acid sustains cancer cell survival and migratory capacity in a hypoxic environment. *Sci. Rep.* **6**, 33026; doi: 10.1038/srep33026 (2016).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2016